tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), Merus (MRUS) and Genfit SA (GNFT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aurinia Pharmaceuticals (AUPHResearch Report), Merus (MRUSResearch Report) and Genfit SA (GNFTResearch Report) with bullish sentiments.

Aurinia Pharmaceuticals (AUPH)

In a report issued on September 19, Joseph Schwartz from SVB Securities reiterated a Buy rating on Aurinia Pharmaceuticals. The company’s shares closed last Tuesday at $7.62, close to its 52-week low of $6.28.

According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -9.2% and a 41.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $18.13, which is a 139.2% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.

See the top stocks recommended by analysts >>

Merus (MRUS)

SVB Securities analyst Andrew Berens maintained a Buy rating on Merus yesterday. The company’s shares closed last Tuesday at $20.09.

According to TipRanks.com, Berens is a 3-star analyst with an average return of 2.0% and a 46.7% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Merus is a Strong Buy with an average price target of $41.60.

Genfit SA (GNFT)

SVB Securities analyst Thomas Smith reiterated a Buy rating on Genfit SA on September 19. The company’s shares closed last Tuesday at $4.15.

According to TipRanks.com, Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 33.0% success rate. Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Madrigal Pharmaceuticals.

Genfit SA has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, implying a 91.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AUPH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles